Biopharma Investor's Letter Dooms Officer Salary Suit

By Rose Krebs (October 31, 2019, 4:03 PM EDT) -- A Delaware vice chancellor on Wednesday tossed an investor suit against biopharmaceutical company Ultragenyx Pharmaceutical Inc. over alleged excessive board salaries, ruling the stockholder's derivative action was procedurally flawed because he had made a presuit litigation demand on the board that was rejected....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!